JPH09263531A - Skin cleaning agent - Google Patents
Skin cleaning agentInfo
- Publication number
- JPH09263531A JPH09263531A JP8075547A JP7554796A JPH09263531A JP H09263531 A JPH09263531 A JP H09263531A JP 8075547 A JP8075547 A JP 8075547A JP 7554796 A JP7554796 A JP 7554796A JP H09263531 A JPH09263531 A JP H09263531A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- extract
- soap
- cleaning agent
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012459 cleaning agent Substances 0.000 title abstract description 5
- 239000000344 soap Substances 0.000 claims abstract description 14
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 12
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 12
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 3
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 claims abstract description 3
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 3
- 239000003599 detergent Substances 0.000 claims description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 6
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 4
- 229960000458 allantoin Drugs 0.000 claims description 4
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 2
- 229960002684 aminocaproic acid Drugs 0.000 claims description 2
- 229940036350 bisabolol Drugs 0.000 claims description 2
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims description 2
- 229960003720 enoxolone Drugs 0.000 claims description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 2
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 2
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 claims description 2
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 claims description 2
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 2
- 229960000401 tranexamic acid Drugs 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 206010040880 Skin irritation Diseases 0.000 abstract description 8
- 231100000475 skin irritation Toxicity 0.000 abstract description 8
- 230000036556 skin irritation Effects 0.000 abstract description 8
- 206010012438 Dermatitis atopic Diseases 0.000 abstract description 3
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 3
- 238000004140 cleaning Methods 0.000 abstract description 3
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 241000196324 Embryophyta Species 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 2
- 208000002474 Tinea Diseases 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000006071 cream Substances 0.000 abstract description 2
- 239000006185 dispersion Substances 0.000 abstract description 2
- 239000002674 ointment Substances 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 240000003377 Shepherdia canadensis Species 0.000 abstract 3
- 235000018324 Shepherdia canadensis Nutrition 0.000 abstract 3
- 235000013399 edible fruits Nutrition 0.000 abstract 3
- 206010012504 Dermatophytosis Diseases 0.000 abstract 1
- 241001460074 Microsporum distortum Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 239000008271 cosmetic emulsion Substances 0.000 abstract 1
- 239000006210 lotion Substances 0.000 abstract 1
- 239000012264 purified product Substances 0.000 abstract 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 6
- 230000007794 irritation Effects 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000037311 normal skin Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 235000004347 Perilla Nutrition 0.000 description 3
- 241000229722 Perilla <angiosperm> Species 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000015898 Bacterial Skin disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- RODZIAKMFCIGPL-UHFFFAOYSA-N P.I.I Chemical compound P.I.I RODZIAKMFCIGPL-UHFFFAOYSA-N 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- 241000580955 Sapindus mukorossi Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- -1 pH regulators Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012449 sabouraud dextrose agar Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013042 solid detergent Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、殺菌作用を有する低刺
激の皮膚洗浄剤に関する。FIELD OF THE INVENTION The present invention relates to a mild skin cleansing agent having a bactericidal action.
【０００２】[0002]
【従来の技術】近年、高度情報化社会におけるストレス
などの誘導因子により、人々は外部環境物質に対して感
受性が高まっている。そのため、アレルギー性や細菌性
などによる皮膚疾患（湿疹、白癬、アトピー性皮膚炎、
尋常性ざそうなど）の罹患者が増加している。これら皮
膚疾患の治療の際、疾患部における感染細菌の除去や治
療の補助的手段として、石鹸洗浄が有効であることが多
い。ここで、疾患部位は刺激に対して敏感であることか
ら、使用する石鹸は低刺激性のもので、かつ感染細菌の
除去のために殺菌作用を有する石鹸が好ましい。しか
し、細菌除去のために殺菌剤を配合した石鹸は、殺菌剤
の皮膚に対する刺激のため湿疹、皮膚炎（かぶれ・ただ
れ）などの皮膚障害があるときには、かえって症状を悪
化させることがあり、皮膚疾患部の洗浄に対して好まし
いものではなかった。2. Description of the Related Art In recent years, people have become more sensitive to external environmental substances due to inducing factors such as stress in an advanced information society. Therefore, allergic and bacterial skin diseases (eczema, ringworm, atopic dermatitis,
Acne vulgaris) is on the rise. In the treatment of these skin diseases, soap washing is often effective as an auxiliary means for removal of infectious bacteria and treatment in the diseased part. Here, since the diseased part is sensitive to irritation, the soap used is preferably a mild soap and a soap having a bactericidal action for removing infectious bacteria. However, soap containing a bactericidal agent to remove bacteria may worsen the symptoms if there is a skin disorder such as eczema or dermatitis (rash / sore) due to irritation of the bactericidal agent on the skin. It was not preferable for cleaning the diseased part.
【０００３】また、特開平２−１６０７９８号公報では
ムクロジ果皮抽出物を有効成分とする抗菌剤が開示され
ているが、ムクロジ果皮抽出物を単独で用いると若干の
皮膚刺激を有するため、そのまま皮膚洗浄剤に配合する
のは困難であった。Further, Japanese Patent Laid-Open No. 2-160798 discloses an antibacterial agent containing an extract of sucrose pericarp as an active ingredient. However, when an extract of sucrose pericarp is used alone, it causes some skin irritation, so that the skin remains intact. It was difficult to mix it with a detergent.
【０００４】[0004]
【発明が解決しようとする課題】本発明は、ムクロジ果
皮抽出物の有する殺菌作用を保持したまま、皮膚刺激を
低減させた皮膚洗浄剤を提供することを目的とする。DISCLOSURE OF THE INVENTION An object of the present invention is to provide a skin cleansing agent having reduced skin irritation while retaining the bactericidal action of the extract of sucrose pericarp.
【０００５】[0005]
【課題を解決するための手段】本発明者らは、前記課題
を解決するために種々検討した結果、ムクロジ果皮抽出
物および抗炎症剤を同時に配合した皮膚洗浄剤は、ムク
ロジ果皮抽出物を単独配合した場合に比べて皮膚刺激が
低減され、さらに殺菌作用はムクロジ果皮抽出物単独の
場合と同等の殺菌力を保持していることを見いだし本発
明を完成した。すなわち本発明は、ムクロジ果皮抽出物
および抗炎症剤を配合することを特徴とする皮膚洗浄剤
である。Means for Solving the Problems As a result of various investigations for solving the above-mentioned problems, the present inventors have found that a skin cleansing agent in which a mukurodi pericarp extract and an anti-inflammatory agent are blended at the same time is a mukurodi pericarp extract alone. It was found that the skin irritation was reduced as compared with the case where it was blended, and the bactericidal action retained the same bactericidal power as that of the case of using the extract of sucrose pericarp alone, and the present invention was completed. That is, the present invention is a skin cleansing agent characterized by containing the extract of perilla peel and an anti-inflammatory agent.
【０００６】本発明においてムクロジ果皮とは、別名延
命皮と呼ばれる、植物ムクロジの果皮である。本発明で
用いるのは、そのムクロジ果皮を常法に従いアルコール
などで抽出したものを精製、粉末化したものである。ま
た、抗炎症剤とは、グリチルリチン酸、グリチルレチン
酸、イプシロンアミノカプロン酸、トラネキサム酸、ビ
サボロール、アラントインなどの通常皮膚外用剤などに
用いられるものであり、それらの塩、エステルなどの類
縁体も包含する。[0006] In the present invention, the sucrose pericarp refers to the pericarp of plant sucrose, which is also referred to as "enmeikin". What is used in the present invention is a product obtained by extracting the sucrose pericarp with alcohol or the like according to a conventional method and then purifying and powdering it. Further, the anti-inflammatory agent is one that is usually used for external skin preparations such as glycyrrhizic acid, glycyrrhetinic acid, epsilon aminocaproic acid, tranexamic acid, bisabolol, and allantoin, and analogs thereof such as salts and esters are also included. .
【０００７】本発明において皮膚洗浄剤とは石鹸、ボデ
ィーソープ、ハンドソープなどの通常使用される形態の
ものである。[0007] In the present invention, the skin cleansing agent is in a commonly used form such as soap, body soap and hand soap.
【０００８】[0008]
【発明の実施の形態】本発明において、ムクロジ果皮抽
出物の配合量は洗浄剤全量中、乾燥物として通常０．０
０５〜１．０重量％、好ましくは０．０１〜０．３重量
％である。抗炎症剤の配合量は洗浄剤全量中、通常０．
０１〜１０．０重量％、好ましくは０．０５〜５．０重
量％配合する。また、抗炎症剤は通常皮膚外用剤などに
用いられるものであるが、特にグリチルリチン酸ジカリ
ウム、グリチルリチン酸モノアンモニウム、β−グリチ
ルレチン酸、グリチルレチン酸ステアリルおよびアラン
トインからなる群から選ばれる１種または２種以上の抗
炎症剤を用いると、皮膚刺激の低減の点で好ましい。BEST MODE FOR CARRYING OUT THE INVENTION In the present invention, the amount of the extract of perilla peel is usually 0.0 as a dry product in the total amount of the detergent.
It is from 05 to 1.0% by weight, preferably from 0.01 to 0.3% by weight. The content of the anti-inflammatory agent is usually 0.
The amount is 01 to 10.0% by weight, preferably 0.05 to 5.0% by weight. Further, the anti-inflammatory agent is usually used for external preparations for the skin, but in particular, one or two selected from the group consisting of dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, β-glycyrrhetinic acid, stearyl glycyrrhetinate and allantoin. The use of the above anti-inflammatory agents is preferable from the viewpoint of reducing skin irritation.
【０００９】本発明の皮膚洗浄剤はムクロジ果皮抽出物
および抗炎症剤の必須成分の他、必要に応じて本発明の
効果を損なわない範囲で、他の洗浄成分、油分、界面活
性剤、保湿剤、ｐＨ調節剤、増粘剤、防腐剤、酸化防止
剤、香料、色素、ＵＶ吸収剤、ビタミン類などの皮膚洗
浄剤に一般に用いられる成分、基剤などを配合すること
ができる。The skin cleansing agent of the present invention contains, in addition to the essential components of the extract of Mukurodi peel and an anti-inflammatory agent, other cleansing ingredients, oils, surfactants, moisturizers, if necessary, within a range not impairing the effects of the present invention. Ingredients, pH regulators, thickeners, preservatives, antioxidants, fragrances, pigments, UV absorbers, vitamins, and other components generally used in skin cleansing agents, bases, and the like can be added.
【００１０】また、本発明の皮膚洗浄剤の剤形は通常の
化粧品、医薬部外品などに用いられる任意の形態、例え
ば化粧品などの可溶化系、乳液、クリームなどの乳化系
あるいは軟膏、粉末分散系、固形などの剤形を使用でき
る。The dosage form of the skin cleansing agent of the present invention may be any form used for ordinary cosmetics, quasi drugs, and the like, such as solubilizing systems for cosmetics, emulsions such as emulsions and creams, ointments and powders. Dosage forms such as dispersions and solids can be used.
【００１１】[0011]
【発明の効果】後記試験例から明らかなように、本発明
によりムクロジ果皮抽出物の殺菌力を損なうことなく、
皮膚に対して低刺激の洗浄剤を提供することが可能とな
った。そのため、特に水虫、アトピー性皮膚炎などの患
部の洗浄に適した洗浄剤を得ることができた。As is apparent from the test examples described below, the present invention does not impair the bactericidal activity of the extract of Mukuroji peel,
It has become possible to provide a cleansing agent that is mild to the skin. Therefore, a cleansing agent suitable for cleaning affected areas such as athlete's foot and atopic dermatitis could be obtained.
【００１２】[0012]
【実施例】次に、実施例および試験例をあげて本発明を
更に詳細に説明する。EXAMPLES Next, the present invention will be described in more detail with reference to Examples and Test Examples.
【００１３】実施例 実施例１および対照例１〜４に示す処方で、機械練り石
鹸の常法により固形洗浄剤を得た。EXAMPLE A solid detergent was obtained by the conventional method of mechanical kneading soap with the formulations shown in Example 1 and Comparative Examples 1 to 4.
【００１４】実施例１ Example 1
【００１５】対照例１ Comparative Example 1
【００１６】対照例２ Comparative Example 2
【００１７】対照例３ Control Example 3
【００１８】対照例４ Control Example 4
【００１９】試験例１ ウサギ（正常皮膚）における皮膚一次刺激性試験 実施例および対照例について、各サンプルの２％水溶液
を浸透させた絆創膏（鳥居薬品株式会社製）を、剪毛し
たウサギ背側部の正常皮膚に貼付し、２４時間後にこれ
を除去し、塗布部位を清拭した。その後、表１に示すＤ
ｒａｉｚｅの判定基準に従い、紅斑及び痂皮の形成と浮
腫の形成を判定した。Test Example 1 Primary Skin Irritation Test in Rabbit (Normal Skin) For Examples and Controls, a 2% aqueous solution of each sample was permeated with a plaster (Torii Pharmaceutical Co., Ltd.) and the dorsal part of the rabbit was shaved. Was applied to normal skin of the above, and after 24 hours, this was removed, and the application site was wiped. After that, D shown in Table 1
The formation of erythema and eschar and the formation of edema were determined according to the Raize criteria.
【００２０】[0020]
【表１】 [Table 1]
【００２１】得られた結果から、下記の式により一次刺
激性インデックス（Ｐ．Ｉ．Ｉ．）を算出し、刺激の程
度を数値化した。From the results obtained, the primary irritation index (P.I.I.) was calculated by the following formula, and the degree of irritation was quantified.
【００２２】[0022]
【数１】 [Equation 1]
【００２３】各サンプルの結果を表に示す。Ｐ．Ｉ．
Ｉ．は数値が小さいほど皮膚刺激が小さいことを示して
いる。The results of each sample are shown in the table. P. I.
I. Indicates that the smaller the value, the smaller the skin irritation.
【００２４】[0024]
【表２】 [Table 2]
【００２５】試験例２ モルモット（損傷皮膚及び正常皮膚）における皮膚一次
刺激性試験 実施例および対照例について、各サンプルの２％水溶液
を浸透させた絆創膏（鳥居薬品株式会社製）を、剪毛し
たモルモット背側部の正常皮膚および「井」の字型に傷
つけた損傷皮膚に貼付し、２４時間後にこれを除去し、
塗布部位を清拭した。その後、Ｄｒａｉｚｅの判定基準
に従い、紅斑及び痂皮の形成と浮腫の形成を判定した。Test Example 2 Primary skin irritation test on guinea pigs (damaged skin and normal skin) For the examples and the control examples, a 2% aqueous solution of each sample was permeated with a plaster (Torii Pharmaceutical Co., Ltd.) and the guinea pig was shaved. Apply to normal skin on dorsal side and damaged skin injured in a "well" shape, remove this after 24 hours,
The application site was wiped clean. Then, the formation of erythema and scab and the formation of edema were determined according to the Draize criterion.
【００２６】各サンプルの結果を表に示す。The results of each sample are shown in the table.
【００２７】[0027]
【表３】 [Table 3]
【００２８】試験例３ ヒトに対する４８時間閉塞塗布試験 試験サンプルの２％水溶液を浸透させた絆創膏（鳥居薬
品株式会社製）を健常人男子２０名の正常皮膚に貼付
し、４８時間後にこれを除去し、塗布部位を清拭した。
絆創膏除去２４時間後に刺激性を判定した。下記判定基
準により、（＋）以上の紅斑を示したものを陽性とし
た。Test Example 3 48-hour occlusion application test on humans A bandage (manufactured by Torii Pharmaceutical Co., Ltd.) impregnated with a 2% aqueous solution of a test sample was applied to normal skin of 20 healthy males and removed 48 hours later. Then, the application site was wiped.
Irritation was determined 24 hours after removal of the bandage. Those showing erythema of (+) or higher according to the following criteria were regarded as positive.
【００２９】[0029]
【表４】 [Table 4]
【００３０】各サンプルの塗布除去直後および塗布除去
翌日の刺激性を判定した。塗布除去直後の評点の平均を
求め、また、同一個体内で、塗布除去翌日の判定が塗布
除去直後と比べ同等以上の判定を示したものを残留刺激
と定義し、その割合を求めた。Immediately after the coating removal of each sample and the day after the coating removal, the irritation was determined. The average of the scores immediately after the removal of the coating was determined, and those in which the determination on the day after the removal of the coating showed the same or higher determination than that immediately after the removal of the coating within the same individual was defined as the residual stimulus, and the ratio thereof was determined.
【００３１】結果を表に示す。The results are shown in the table.
【００３２】[0032]
【表５】 [Table 5]
【００３３】試験例４ 石鹸の細菌に対する抗菌活性 サブロー寒天培地を用いた寒天平板拡散法で測定した。Test Example 4 Antibacterial activity of soap against bacteria It was measured by the agar plate diffusion method using Sabouraud agar medium.
【００３４】濾紙ディスクに各サンプルをしみ込ませ、
被験菌（Ｔ．ｒｕｂｒｕｍ）を接種分散させた寒天平板
上に接着させ、３０℃で３日間培養した。培養終了後に
濾紙の周囲の菌の発育が阻止される透明帯（発育阻止
帯）の直径を求めた。結果を表に示す。Soak each sample in a filter paper disk,
The test bacterium (T. rubrum) was adhered to an agar plate on which an inoculum was dispersed, and cultured at 30 ° C. for 3 days. After the culture was completed, the diameter of the transparent zone (growth inhibition zone) around the filter paper, where growth of bacteria was inhibited, was determined. The results are shown in the table.
【００３５】[0035]
【表６】 [Table 6]
【００３６】本発明の洗浄剤は、ムクロジ果皮抽出物の
抗菌活性を損なっていないことが解る。It can be seen that the cleaning agent of the present invention does not impair the antibacterial activity of the extract of perilla extract.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 ＦＩ 技術表示箇所 Ａ６１Ｋ 35/78 ＡＤＢ Ａ６１Ｋ 35/78 ＡＤＢＣ Ｃ１１Ｄ 3/382 Ｃ１１Ｄ 3/382 3/48 3/48 (72)発明者 漆崎 文男 東京都豊島区高田３丁目24番１号 大正製 薬株式会社内─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI Technical display location A61K 35/78 ADB A61K 35/78 ADBC C11D 3/382 C11D 3/382 3/48 3/48 ( 72) Inventor Fumio Urushizaki 3-24-1, Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd.
Claims (3)
合することを特徴とする皮膚洗浄剤。1. A skin cleansing agent comprising a sucrose pulp extract and an anti-inflammatory agent.
レチン酸、イプシロンアミノカプロン酸、トラネキサム
酸、ビサボロール、アラントインまたはそれらの類縁体
からなる郡から選ばれる１種または２種以上である請求
項１記載の皮膚洗浄剤。2. The skin according to claim 1, wherein the anti-inflammatory agent is one or more selected from the group consisting of glycyrrhizic acid, glycyrrhetinic acid, epsilon aminocaproic acid, tranexamic acid, bisabolol, allantoin and their analogs. Washing soap.
ム、グリチルリチン酸モノアンモニウム、β−グリチル
レチン酸、グリチルレチン酸ステアリルおよびアラント
インからなる群から選ばれる１種または２種以上である
請求項１記載の皮膚洗浄剤。3. The skin cleanser according to claim 1, wherein the anti-inflammatory agent is one or more selected from the group consisting of dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, β-glycyrrhetinic acid, stearyl glycyrrhetinate and allantoin. .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8075547A JPH09263531A (en) | 1996-03-29 | 1996-03-29 | Skin cleaning agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8075547A JPH09263531A (en) | 1996-03-29 | 1996-03-29 | Skin cleaning agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH09263531A true JPH09263531A (en) | 1997-10-07 |
Family
ID=13579340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8075547A Pending JPH09263531A (en) | 1996-03-29 | 1996-03-29 | Skin cleaning agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH09263531A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004010958A3 (en) * | 2002-07-31 | 2004-06-10 | Shaklee Corp | A method for maximizing scalp health and inducing enhanced visual and tactile hair quality |
| JP2007326806A (en) * | 2006-06-07 | 2007-12-20 | Maruzen Pharmaceut Co Ltd | Bacteriostat, and detergent and skin cosmetic |
| CN103961275A (en) * | 2013-02-03 | 2014-08-06 | 广州无患子生物科技有限公司 | Daily necessities containing all-natural source surfactant and preparation method thereof |
| JP2017007984A (en) * | 2015-06-24 | 2017-01-12 | 一丸ファルコス株式会社 | Skin cleansing agent which improves resident skin bacteria balance |
-
1996
- 1996-03-29 JP JP8075547A patent/JPH09263531A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004010958A3 (en) * | 2002-07-31 | 2004-06-10 | Shaklee Corp | A method for maximizing scalp health and inducing enhanced visual and tactile hair quality |
| US7025955B2 (en) | 2002-07-31 | 2006-04-11 | Shaklee Corporation | Method for maximizing scalp health and inducing enhanced visual and tactile hair quality |
| JP2007326806A (en) * | 2006-06-07 | 2007-12-20 | Maruzen Pharmaceut Co Ltd | Bacteriostat, and detergent and skin cosmetic |
| CN103961275A (en) * | 2013-02-03 | 2014-08-06 | 广州无患子生物科技有限公司 | Daily necessities containing all-natural source surfactant and preparation method thereof |
| JP2017007984A (en) * | 2015-06-24 | 2017-01-12 | 一丸ファルコス株式会社 | Skin cleansing agent which improves resident skin bacteria balance |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI115606B (en) | NO synthase inhibitors | |
| EP3359124B1 (en) | Composition comprising niacinamide and picolinamide | |
| CN111295190A (en) | Use of nicotinamide for microbiome balance | |
| FR2916634A1 (en) | Synergistic combination, useful e.g. as regulating agent of microbial flora of skin and to prepare cosmetic or pharmaceutical composition to treat oily or mixed skin, of fructo-oligosaccharides and inducer of antimicrobial peptide | |
| TW201416071A (en) | Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne | |
| JPH06199647A (en) | Skin beautifying cosmetic | |
| US3663716A (en) | Method of treating acne with benzyl alcohol | |
| JP2006241005A (en) | Skin aging-preventing agent and cosmetic | |
| JPH09263531A (en) | Skin cleaning agent | |
| JP2022527901A (en) | Use of polylysine dendrimers in the prevention and management of acne-prone and acne-prone skin | |
| JP2001172167A (en) | Cleanser composition | |
| JP2006022090A (en) | Inflammation inhibitor composed of pyrrolidonecarboxylic acid zinc salt | |
| JP2006298814A (en) | Skin lotion for acne | |
| EP0909557A1 (en) | Use of honey as an agent for decreasing micro-organisms adhesion | |
| AU2020405222B2 (en) | Personal care compositions and methods for the same | |
| JPH11100324A (en) | Composition for treating pimple | |
| WO2016033899A1 (en) | Dandruff removing composition for adjusting scalp oil balance | |
| JP2003104886A (en) | Skin care composition | |
| JP3505003B2 (en) | External preparation | |
| JPH03112912A (en) | Cosmetic composition | |
| KR19990039050A (en) | Acne prevention and treatment containing wasp venom extract | |
| KR20010040494A (en) | Anti-enzyme compositions comprising ethylenediamine disuccinic acid | |
| JP4222973B2 (en) | Elastase activity inhibitors and cosmetics | |
| JPH10265364A (en) | Lipase inhibitor and external preparation for skin for pimple | |
| JP2000143485A (en) | Composition for controlling aging of dermal cell |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040820 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040907 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050105 |